VitalCore Technologies Launches First Continuous Blood Pressure Monitoring Band Category
SAN FRANCISCO, Nov. 24, 2025
VitalCore Technologies today introduced the VitalTrack BP Band, establishing the industry’s first dedicated continuous blood pressure monitoring wearable category. The device combines photoplethysmography (PPG) sensor technology with proprietary AI algorithms to deliver beat-to-beat blood pressure readings without traditional cuffs, representing a fundamental shift from episodic measurement to continuous cardiovascular surveillance.
The wrist-worn device captures arterial waveform data through high-fidelity optical sensors and accelerometers, processing 10,000+ data points per minute via on-device machine learning models. Clinical validation data demonstrate a mean absolute difference of 5.8 mmHg compared to intra-arterial reference standards, exceeding FDA acceptance criteria for wearable blood pressure monitors. The band operates continuously for 72 hours on a single charge, syncs via Bluetooth Low Energy to a HIPAA-compliant mobile platform, and integrates directly with electronic health record systems through FHIR-standard APIs.
The launch arrives as the wearable blood pressure monitoring market experiences accelerating expansion, projected to grow from $3.2 billion in 2025 to $13.2 billion by 2035 at a 15.1% compound annual growth rate, according to Future Market Insights. Wearable devices specifically captured 43% of the AI-enabled blood pressure monitoring segment in 2024, driven by rising hypertension prevalence affecting 1.3 billion people globally and growing clinical acceptance of remote patient monitoring. Recent industry analysis indicates the AI in blood pressure monitoring market alone will reach $7.6 billion by 2032, expanding at 30.08% annually as healthcare systems shift toward preventive care models. The convergence of sensor miniaturization, edge computing capabilities, and reimbursement changes for remote therapeutic monitoring has created optimal market conditions for continuous monitoring solutions.
VitalCore has secured FDA 510(k) clearance for the VitalTrack BP Band as a Class II medical device, with clinical trials conducted across three major cardiology centers involving 450 participants over six months. The studies demonstrated 98.2% measurement availability during daily activities and successful detection of nocturnal blood pressure dipping patterns in 94% of users—critical data points for assessing cardiovascular risk that traditional cuff-based devices cannot capture consistently. The device also received CE marking for European distribution and is pending regulatory review in Japan and South Korea.
“For decades, we’ve accepted that blood pressure management means brief snapshots taken in clinical settings,” said Dr. Sarah Chen, co-founder and CEO of VitalCore Technologies. “Our continuous monitoring architecture reveals the complete hemodynamic story—how stress, sleep, medication timing, and daily activities influence cardiovascular health in real time. This isn’t just incremental improvement; it’s the difference between a photograph and a motion picture of patient physiology.”
The VitalTrack BP Band will retail for $399, with a companion clinical dashboard available through subscription for healthcare providers. Initial distribution launches through the company’s direct-to-consumer platform and select cardiology practices in 15 U.S. states beginning December 1, 2025. Enterprise partnerships with three major health systems and two pharmaceutical clinical trial divisions are already underway, positioning the device for both chronic disease management and research applications. Home care settings represent 53.8% of the addressable market, reflecting strong consumer demand for autonomous health monitoring solutions.
About VitalCore Technologies
Founded in 2021 by a team of biomedical engineers and practicing cardiologists from Stanford and UCSF, VitalCore Technologies develops next-generation cardiovascular monitoring solutions that bridge consumer wearables and clinical-grade diagnostics. The company holds 12 issued patents in optical sensing and hemodynamic modeling, with an additional 18 applications pending. VitalCore is headquartered in San Francisco with research facilities in Boston and regulatory offices in Dublin and Singapore. The company has raised $47 million in Series B funding led by HealthTech Ventures and Pacific Growth Capital.
Media Contact
Sarha Al-Mansoori
Director of Corporate Communications
G42
Email: media@g42.ai
Phone: +971 2555 0100
Website: www.g42.ai
